Diabetes remission is possible — but there's a catch, new study finds
Diabetes remission is relatively rare, and doctors and researchers have long known that weight loss — particularly through bariatric surgery — is one main way people with diabetes can achieve it. But the new research offers hope that people can also achieve remission through less extreme methods, while noting the challenges of sustaining it.
Previous research has found that about 3% of people with diabetes achieve remission. However, those studies included people who underwent bariatric surgery, while the new Kaiser study excluded people in that category.
'Our study shows that diabetes remission is possible even outside of bariatric surgery, or outside of tightly controlled clinical trials,' said Luis Rodriguez, a research scientist at Kaiser Permanente Division of Research and the study's senior author. 'This is a hopeful message because we know remission isn't limited only to intensive interventions.'
The study, published Wednesday in Diabetes Care, included about 560,000 adults with Type 2 diabetes in Hawaii, California, Pennsylvania, Minnesota, Wisconsin and Michigan between 2014 and 2023.
It found that about 16,000 adults, or roughly 3% of the study participants, went into remission after they stopped taking glucose-lowering medications. Most people in the study took Metformin, a common diabetes drug.
Younger people, aged 18 to 29, were more likely to go into remission than adults 75 and older. People who were diagnosed with diabetes more recently — those who had the disease for less than a year, compared to those who had it for four or more years — were also more likely to achieve remission.
The study defined remission as having a hemoglobin A1c of less than 6.5% for at least three months after stopping glucose-lowering medications. A1c is a blood test that measures the average level of blood sugar of the past three months. Anything below 5.7% is considered normal, 5.7% to 6.4% is prediabetic, and 6.5% or higher is diabetic.
People who started with a lower baseline A1c, 7% or lower, were more likely to go into remission compared to those with a higher baseline A1c, 11% or higher.
The study did not examine exactly how people achieved remission, such as how they changed their diet and exercise habits. But remission is achieved primarily through weight loss, so patients who went into remission mostly did it by losing weight via modifications to diet and lifestyle, Rodriguez said.
Among the participants who achieved remission, 57% lost at least 3% of their body weight.
'The research empowers patients who have Type 2 diabetes because it offers them hope and motivation, especially patients who are in early stages of Type 2 diabetes,' Rodriguez said. 'It allows them to know that the earlier they act, the better the chances of achieving remission.'
However, remission was hard to sustain. About 37% of people who initially went into remission had to go back on medication over the subsequent three years, the study found.
A very small number of people in the study were taking GLP-1 receptor agonists, the class of drugs that includes Ozempic. This is mostly because the study stopped enrolling participants in mid-2020, before these drugs became more accessible and popular. GLP-1 drugs were approved about 20 years ago for Type 2 diabetes, but only in the last few years became more widely used for weight loss.
But the few study participants who were on weight loss drugs were less likely to achieve remission, probably because these medications are often used by patients with more complex or severe cases of diabetes.
More research is needed to determine whether remission should be the goal, and whether it is better than managing diabetes through medication. But preliminary studies and patients' experiences suggest that remission means lower risk for long-term diabetes complications like heart disease, kidney disease and premature mortality.
'Our study doesn't suggest that diabetes is easy to reverse, but it does show that with the right support and timely interventions, some patients can achieve remission,' Rodriguez said. 'We hope this research can spark more conversations with patients and providers about remission as a goal, not just diabetes management. We also hope it encourages further studies into how to make remission more achievable for more patients.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
3 days ago
- Medscape
Add-On Lobeglitazone Boosts Glycemic Control in T2D
TOPLINE: Patients with type 2 diabetes (T2D) who responded inadequately to sitagliptin plus metformin experienced improvements in glycemic control and insulin sensitivity after lobeglitazone was added to their regimen. METHODOLOGY: Metformin and DPP-4 inhibitors such as sitagliptin are widely used for glycemic control in patients with T2D; however, the choice of which agent to add when these therapies fail to achieve target blood glucose levels remains unclear. Researchers in Korea conducted a phase 3 trial from April 2018 to December 2021 to evaluate the efficacy and safety of adding lobeglitazone to the dual therapy regimen of metformin (≥ 1000 mg/d) and sitagliptin (100 mg/d). The study included 231 patients with T2D (mean age, 58.65 years; 56.52% men) whose A1c ranged from 7.0% to 10.0% despite receiving the dual therapy. After a 2-week run-in period, patients were randomly assigned to receive either a 0.5 mg/d dose of lobeglitazone (n = 116) or placebo (n = 115) alongside metformin and sitagliptin for 24 weeks, followed by a 28-week open-label phase in which all patients received lobeglitazone. The primary endpoint was the change from baseline in mean A1c at 24 weeks. Secondary endpoints included changes in additional glycemic and lipid parameters and safety outcomes. TAKEAWAY: At week 24, mean A1c levels were 1.03% lower in patients who received lobeglitazone vs placebo (95% CI, -1.23% to -0.82%), with the reduction being maintained until 52 weeks; those who switched from placebo to lobeglitazone at week 24 also saw a reduction in A1c levels by week 52. Additionally, at week 24, a higher proportion of patients receiving lobeglitazone vs placebo achieved A1c levels < 6.5% (27.14% vs 0.87%) and < 7% (53.04% vs 13.04%; both P < .0001). The addition of lobeglitazone to dual therapy significantly improved insulin sensitivity markers compared with placebo at week 24, with effects sustained till week 52; additionally, administration of lobeglitazone reduced low-density lipoprotein cholesterol levels. The incidence of adverse events was not significantly different between the two groups; the incidence of edema and weight gain in some patients receiving lobeglitazone aligned with the known effects of thiazolidinediones. IN PRACTICE: 'The observed improvements in various glucose-related metabolic factors and lipid metabolism indicators with lobeglitazone coadministration may provide valuable evidence for long-term blood glucose management and cardiovascular risk reduction,' the authors of the study wrote. SOURCE: This study was led by Eun-Gyoung Hong, MD, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, South Korea. It was published online in Diabetes, Obesity and Metabolism. LIMITATIONS: A longer follow-up might be needed to fully evaluate the sustained effects of the study outcomes and potential side effects. DISCLOSURES: This study received funding from Chong Kun Dang Pharmaceutical Company. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
4 days ago
- Yahoo
3 Reasons to Buy Medtronic Stock
Key Points Medtronic is separating out its lower-margin diabetes care segment. It's also pouncing on a massive opportunity in robotic-assisted surgery. The healthcare leader has a terrific dividend-growth track record. 10 stocks we like better than Medtronic › Medical device specialist Medtronic (NYSE: MDT) has not been the best of investments over the past five years. The stock has significantly lagged the market over this period, thanks to weak business fundamentals, including slow revenue growth. The healthcare giant now faces additional obstacles, such as the threat of steeper tariffs due to President Donald Trump's aggressive trade policies. Even amid all that, Medtronic has plenty of redeeming qualities and could still be a solid investment for long-term investors. Here are three reasons why. 1. Medtronic is spinning off its diabetes care unit Medtronic recently announced that it will be spinning off its diabetes care unit, which will become a stand-alone, publicly traded company. Although sales of diabetes products have been growing faster than the rest of Medtronic's business, they have also been a drag on margins. During the company's fiscal year 2025, which ended on April 25, diabetes care accounted for 8% of revenue but only 4% of operating profits. Medtronic's other segments are not growing their sales as quickly, but they have more profitable margins. In an environment where the company may face higher manufacturing costs due to tariffs, management has chosen to focus on higher-margin opportunities. Diabetes care was also the healthcare specialist's only consumer-facing business; the others offer products to healthcare providers. The move could help Medtronic navigate the macroeconomic landscape better if Trump's tariffs remain in place. That's especially the case if the company can find other lucrative revenue growth opportunities. 2. A significant opportunity in robotic-assisted surgery Medtronic has been developing its robotic-assisted surgery (RAS) system, Hugo, for years. It has been in use in other countries, though it's yet to get the regulatory nod in the United States. The medical device specialist decided to pursue this opportunity because the RAS market is severely underpenetrated. Intuitive Surgical's da Vinci system dominates the field and faces little competition for the range of procedures for which it's approved. Yet a couple of years ago, Medtronic pointed out that of all the procedures that could be performed robotically, fewer than 5% were. And over the long run, the demand for these kinds of surgeries will increase along with the world's aging population, since seniors are far more likely to face health issues that call for these kinds of interventions. The good news is that Medtronic's Hugo system recently completed clinical trials in the U.S. for urologic procedures. The company has requested clearance from the U.S. Food and Drug Administration for that indication. It should be the first of many. The Hugo system could eventually become a crucial part of Medtronic's growth strategy and help improve its financial results over the long term, given the significant white space available in the industry. 3. A soon-to-be Dividend King Despite Medtronic's recent challenges, the company has continued to pay and raise its dividends. In fact, the company has raised dividends for 48 consecutive years. Most businesses don't survive nearly five decades, let alone pay dividends for that long. Medtronic's ability to do so speaks volumes about its underlying business. It's a well-established leader in its niche of the healthcare market, with significant footprint in the industry and a long and successful history of navigating this deeply regulated sector. All of those factors make Medtronic an excellent pick for income-seeking investors. It should continue rewarding shareholders with payout increases for a long time -- and in two years, it should become a Dividend King. Medtronic may not be one of the most exciting artificial intelligence (AI) leaders capturing Wall Street's attention, although the company is implementing AI across its business in ways that could pay off in the long run. Regardless, its recent moves in shedding its diabetes care segment and seeking clearance for its Hugo system, along with its consistent dividend streak, make Medtronic a reliable company to invest in for the long haul. Do the experts think Medtronic is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Medtronic make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Prosper Junior Bakiny has positions in Intuitive Surgical. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. 3 Reasons to Buy Medtronic Stock was originally published by The Motley Fool
San Francisco Chronicle
4 days ago
- San Francisco Chronicle
Diabetes remission is possible — but there's a catch, new study finds
People with Type 2 diabetes — especially those with less severe diabetes, and those who are in earlier stages of the disease — can achieve remission through diet and lifestyle changes, according to a new study from the Kaiser Permanente Division of Research. Diabetes remission is relatively rare, and doctors and researchers have long known that weight loss — particularly through bariatric surgery — is one main way people with diabetes can achieve it. But the new research offers hope that people can also achieve remission through less extreme methods, while noting the challenges of sustaining it. Previous research has found that about 3% of people with diabetes achieve remission. However, those studies included people who underwent bariatric surgery, while the new Kaiser study excluded people in that category. 'Our study shows that diabetes remission is possible even outside of bariatric surgery, or outside of tightly controlled clinical trials,' said Luis Rodriguez, a research scientist at Kaiser Permanente Division of Research and the study's senior author. 'This is a hopeful message because we know remission isn't limited only to intensive interventions.' The study, published Wednesday in Diabetes Care, included about 560,000 adults with Type 2 diabetes in Hawaii, California, Pennsylvania, Minnesota, Wisconsin and Michigan between 2014 and 2023. It found that about 16,000 adults, or roughly 3% of the study participants, went into remission after they stopped taking glucose-lowering medications. Most people in the study took Metformin, a common diabetes drug. Younger people, aged 18 to 29, were more likely to go into remission than adults 75 and older. People who were diagnosed with diabetes more recently — those who had the disease for less than a year, compared to those who had it for four or more years — were also more likely to achieve remission. The study defined remission as having a hemoglobin A1c of less than 6.5% for at least three months after stopping glucose-lowering medications. A1c is a blood test that measures the average level of blood sugar of the past three months. Anything below 5.7% is considered normal, 5.7% to 6.4% is prediabetic, and 6.5% or higher is diabetic. People who started with a lower baseline A1c, 7% or lower, were more likely to go into remission compared to those with a higher baseline A1c, 11% or higher. The study did not examine exactly how people achieved remission, such as how they changed their diet and exercise habits. But remission is achieved primarily through weight loss, so patients who went into remission mostly did it by losing weight via modifications to diet and lifestyle, Rodriguez said. Among the participants who achieved remission, 57% lost at least 3% of their body weight. 'The research empowers patients who have Type 2 diabetes because it offers them hope and motivation, especially patients who are in early stages of Type 2 diabetes,' Rodriguez said. 'It allows them to know that the earlier they act, the better the chances of achieving remission.' However, remission was hard to sustain. About 37% of people who initially went into remission had to go back on medication over the subsequent three years, the study found. A very small number of people in the study were taking GLP-1 receptor agonists, the class of drugs that includes Ozempic. This is mostly because the study stopped enrolling participants in mid-2020, before these drugs became more accessible and popular. GLP-1 drugs were approved about 20 years ago for Type 2 diabetes, but only in the last few years became more widely used for weight loss. But the few study participants who were on weight loss drugs were less likely to achieve remission, probably because these medications are often used by patients with more complex or severe cases of diabetes. More research is needed to determine whether remission should be the goal, and whether it is better than managing diabetes through medication. But preliminary studies and patients' experiences suggest that remission means lower risk for long-term diabetes complications like heart disease, kidney disease and premature mortality. 'Our study doesn't suggest that diabetes is easy to reverse, but it does show that with the right support and timely interventions, some patients can achieve remission,' Rodriguez said. 'We hope this research can spark more conversations with patients and providers about remission as a goal, not just diabetes management. We also hope it encourages further studies into how to make remission more achievable for more patients.'
